Compare Organon & Co. Common Stock (OGN) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Texas Instruments Incorporated — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Texas Instruments Incorporated trades at $279.4 (market cap $262.88B). The key difference: Texas Instruments Incorporated is far larger — about 72.6× Organon & Co. Common Stock's market cap, and Texas Instruments Incorporated pays the higher dividend (2.11%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Texas Instruments Incorporated for 77 Days on average.
| OGN | TXN | |
|---|---|---|
Market Cap | $3.62B | $262.88B |
Volume | 2,892,999 | 5,600,379 |
Sector | Health | Technology |
52-Week High | $13.81 | $332.35 |
52-Week Low | $5.70 | $153.33 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $11.04B | $269.93B |
Dividend Yield | 0.58% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Texas Instruments (TXN) trades at $281.74, down 0.7% on the day, with a neutral technical signal. The stock shows strong profitability with a 31.11% net income margin and 34.97% ROE, though valuation ratios like a P/E of 43.75 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and data center sales growth is a key driver, with news highlighting a 55% year-to-date gain as of September 2026.
The outlook is positive with a consensus price target of $325, implying 15% upside, supported by AI and industrial demand. Risks include high debt-to-asset ratio of 40.61% and semiconductor cycle volatility. Analyst sentiment is mixed but leans bullish with 48% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
